KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to $1.2 million.

  • Biocryst Pharmaceuticals' Depreciation & Amortization (CF) rose 7.50% to $43,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $180,000, marking a year-over-year increase of 1.69%. This contributed to the annual value of $1.2 million for FY2024, which is 24.71% down from last year.
  • As of FY2024, Biocryst Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.2 million, which was down 24.71% from $1.7 million recorded in FY2023.
  • Biocryst Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $1.7 million during FY2023, with a 5-year trough of $748,000 in FY2020.
  • In the last 3 years, Biocryst Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $1.4 million in 2022 and averaged $1.4 million.
  • Per our database at Business Quant, Biocryst Pharmaceuticals' Depreciation & Amortization (CF) soared by 84.94% in 2022 and then dropped by 24.71% in 2024.
  • Yearly analysis of 5 years shows Biocryst Pharmaceuticals' Depreciation & Amortization (CF) stood at $748,000 in 2020, then rose by 3.88% to $777,000 in 2021, then spiked by 84.94% to $1.4 million in 2022, then rose by 15.17% to $1.7 million in 2023, then fell by 24.71% to $1.2 million in 2024.